Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-11-10
Based on 113 first isolates · ICU · Skin / wound infection · 2023-11-12 → 2024-11-10
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 51 % (42 %–60 %)
Best two-drug combination: vancomycin + meropenem covers 100 % (97 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (12 %), Proteus mirabilis (10 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
51 %
33 %
n = 9
meropenem MEM
trend · Pseudomonas aeruginosa reserve
49 %
67 %
n = 9
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
45 %
56 %
n = 9
42 %
56 %
n = 9
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
36 %
11 %
n = 9
ceftriaxone CRO
trend · Escherichia coli
32 %
33 %
n = 9
28 %
33 %
n = 9
28 %
33 %
n = 9
12 %
22 %
n = 9
mecillinam MEC
not for this site
0 %
0 %
n = 9
trimethoprim TMP
not for this site
0 %
0 %
n = 9
nitrofurantoin NIT
not for this site
0 %
0 %
n = 9

Most likely organisms for this profile

Staphylococcus aureus
39 %
Pseudomonas aeruginosa
14 %
Enterococcus faecalis
12 %
Escherichia coli
12 %
Proteus mirabilis
10 %
Klebsiella pneumoniae
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.